Valeant Pharmaceuticals Intl Inc  

(Public, TSE:VRX)   Watch this stock  
Find more results for VRX
39.39
-0.75 (-1.87%)
Aug 29 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 39.03 - 40.68
52 week 24.32 - 325.49
Open 40.28
Vol / Avg. 1.04M/1.25M
Mkt cap 13.42B
P/E     -
Div/yield     -
EPS -3.71
Shares 341.19M
Beta -0.23
Inst. own 83%
Oct 17, 2016
Q3 2016 Valeant Pharmaceuticals International Inc Earnings Release (Estimated) Add to calendar
Sep 7, 2016
Valeant Pharmaceuticals International Inc at Wells Fargo Securities Healthcare Conference - 3:30PM EDT - Add to calendar
Aug 9, 2016
Q2 2016 Valeant Pharmaceuticals International Inc Earnings Call
Aug 9, 2016
Pharming Announces Acquisition of all North American Commercialisation Rights to RUCONEST´┐Ż From Valeant Pharmaceuticals International Inc Conference Call
Aug 9, 2016
Q2 2016 Valeant Pharmaceuticals International Inc Earnings Release
Jun 14, 2016
Valeant Pharmaceuticals International Inc Annual Shareholders Meeting
Jun 10, 2016
Valeant Pharmaceuticals International Inc Annual Shareholders Meeting (Estimated)
Jun 7, 2016
Q1 2016 Valeant Pharmaceuticals International Inc Earnings Release
Jun 7, 2016
Q1 2016 Valeant Pharmaceuticals International Inc Earnings Call
  

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -12.56% -2.75%
Operating margin 3.33% 14.43%
EBITD margin - 45.71%
Return on average assets -2.52% -0.76%
Return on average equity -22.14% -5.21%
Employees 22,000 -
CDP Score - -

Address

2150 Saint-Elzear Blvd W
LAVAL, QC H7L 4A8
Canada
+1-514-7446792 (Phone)
+1-514-7446272 (Fax)

Website links

Description

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It operates through two segments: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses on primarily on branded generics, OTC products and medical devices. Its pharmaceutical products include Xifaxan, Solodyn and Glumetza. Its OTC products include PreserVision, CeraVe, Biotrue and Boston. Its other generic products include Latanoprost and Metronidazole. Its ophthalmic surgical products include intraocular lenses, such as Akreos, enVista, Crystalens and Trulign.

Officers and directors

Joseph C. Papa Chairman of the Board, Chief Executive Officer
Age: 60
Paul S. Herendeen Chief Financial Officer, Executive Vice President - Finance
Age: 60
Pavel Mirovsky President, General Manager, Europe
Age: 65
Christina Ackermann Executive Vice President, General Counsel
Thomas Appio Executive Vice President, President - Asia Pacific
Ari S. Kellen Executive Vice President, Company Group Chairman
Age: 52
Robert L. Rosiello Executive Vice President - Corporate Development and Strategy
Age: 58
Anne C. Whitaker Executive Vice President
Age: 48
Thomas W. Ross Sr. Lead Independent Director
Age: 65
William A. Ackman Independent Director
Age: 49